News | January 26, 2012

Heart Hospital of Austin Among First Approved for TAVR Since FDA Clearance

January 26, 2012 — Heart Hospital of Austin opened a heart valve clinic, the first of its kind in the region. The clinic gives new hope to patients with severe aortic stenosis who were previously considered inoperable, offering a multidisciplinary approach to evaluating such cases. Interventional cardiologists and cardiac surgeons at the clinic will collaboratively identify patients who may be eligible for a new, catheter-based valve replacement procedure -- transcatheter aortic valve replacement (TAVR) -- instead of traditional, open-chest procedures. Heart Hospital of Austin is among the first sites in the nation to receive this TAVR technology since the U.S. Food and Drug Administration (FDA) approved it in November 2011.

"This is truly a collaborative approach to valve replacement that will provide another option for patients who are not candidates for open-chest surgery due to advanced age, or because they are too ill or suffering from additional medical conditions," Faraz Kerendi, M.D., a cardiothoracic surgeon at Cardiothoracic and Vascular Surgeons, which practices at Heart Hospital of Austin, said. "Prior to this procedure … [patients] were often given only months to live."

Severe aortic stenosis is a condition in which the opening of the aortic valve becomes narrow, restricting blood flow from the heart.

"Over time, the valve can become calcified, preventing it from opening and releasing the blood properly," Juhana Karha, M.D., an interventional cardiologist at Heart Hospital of Austin and with Austin Heart, said. "Open-chest surgery is the traditional treatment method for this condition, but catheter-based valve replacement gives hope to patients who cannot undergo surgery for a variety of reasons."

Symptoms of severe aortic stenosis include chest pain and chest pressure. It can also cause blood to back up into the lungs, resulting in shortness of breath and other breathing problems. Left untreated, this condition is often fatal.

Transcatheter aortic valve replacement consists of inserting a valve — which has been developed to shrink down to the size of a pencil —  through the groin via catheter, up to the aorta. After the catheter is advanced through the aorta and aortic valve, it is positioned and then opened with a balloon.

Transcatheter aortic valve replacement results in a shorter recovery time — one to two weeks, versus six to eight weeks for traditional surgery — and a much smaller incision. More importantly, it prevents the need for physicians to utilize a heart bypass machine. This new technology allows the patient's heart to beat on its own throughout the entire procedure.

The first transcatheter aortic valve replacement procedure is expected to take place in February.

For more information: www.hearthospitalofaustin.com, www.austinheart.com

Related Content

Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init